Efficacy of anidulafungin against Aspergillus niger in vitro and in vivo

Int J Antimicrob Agents. 2011 Oct;38(4):360-3. doi: 10.1016/j.ijantimicag.2011.06.008. Epub 2011 Aug 6.

Abstract

In this study, anidulafungin (AFG) showed high in vitro activity against 10 isolates of Aspergillus niger by broth microdilution and disk diffusion methods. The efficacy of AFG at 1, 5 and 10 mg/kg was tested against six of the isolates in a murine model of disseminated infection. AFG was able to reduce mortality, showing survival rates of 70-100%, 60-100% and 30-60% in mice treated with AFG at 10, 5 and 1 mg/kg, respectively. AFG also showed a dose-response efficacy in reducing tissue burden in kidneys and spleen. A parallel experiment demonstrated that administration of AFG did not reduce serum concentrations of galactomannan in mice. Histopathological studies confirmed the efficacy of AFG.

MeSH terms

  • Anidulafungin
  • Animals
  • Antifungal Agents / pharmacology*
  • Antifungal Agents / therapeutic use
  • Aspergillosis / drug therapy*
  • Aspergillosis / microbiology*
  • Aspergillosis / mortality
  • Aspergillosis / pathology
  • Aspergillus niger / drug effects*
  • Aspergillus niger / enzymology
  • Aspergillus niger / isolation & purification
  • Aspergillus niger / pathogenicity
  • Colony Count, Microbial
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Echinocandins / pharmacology*
  • Echinocandins / therapeutic use
  • Male
  • Mice
  • Microbial Sensitivity Tests / methods
  • Survival Rate
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Echinocandins
  • Anidulafungin